Sun Pharmaceutical Industries Limited witnessed a sharp sell-off in the morning trade on Friday. Shares slipped nearly 4 percent following reports indicating the company is advancing with a binding $12 billion offer for Organon & Co.
The stock was trading at Rs 1,653.50 on the NSE, marking a decline of Rs 63.60 or 3.70 percent. This movement highlights investor reaction to the deepening news surrounding the potential mega-merger.
Developments in the Organon Acquisition Bid
An Economic Times report detailed that the Mumbai-based drugmaker has concluded over three months of rigorous due diligence. The company is reportedly now finalizing the necessary financing package.This progress signals that a firm offer could be submitted in the coming weeks. If executed, this transaction could represent the largest global M&A deal involving an Indian pharmaceutical company.
Strategic Push for Global Expansion
The discussions around Organon are building on Sun Pharma's long-term strategic goals. Chairman Dilip Shanghvi has consistently stressed the importance of innovation for Indian drugmakers.He emphasized that while maintaining strength in generics, acquisitions are viewed as a critical mechanism for scaling up the industry.
Sun Pharma had previously made a non-binding offer for Organon before commencing due diligence in January.
Context Surrounding the Deal Dynamics
The interest in Organon is rooted in the US-based firm's strategic realignment. A more intensive evaluation began late last month.This period followed Organon's sale of its JADA post-partum haemorrhage (PPH) treatment system. That system was sold to Laborie Medical for up to $465 million as part of a strategic pivot.
An industry insider familiar with the talks suggested that despite recent global volatility, Sun Pharma has significantly increased its pace recently. This executive noted that at such an advanced stage, the move appears to be a major, calculated attempt to secure a win.
As of this report, Sun Pharma has yet to issue any official statement regarding the reported developments.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.